Advanced Filters
noise

Systemic Lupus Erythematosus Clinical Trials

A listing of Systemic Lupus Erythematosus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 289 clinical trials
I Ioannis Parodis, MD PhD | Associate Professor

Per-protocol Repeat Kidney Biopsy in Incident Cases of Lupus Nephritis

Lupus nephritis (LN) is one of the most severe complications of systemic lupus erythematosus (SLE). Among people living with SLE, 35-60% will develop LN during the course of the disease. This complication is one of the factors that contribute to deterioration of the renal function. Some centres perform kidney biopsies …

18 years of age All Phase N/A

A Study of Clinical Characteristics ,Risk Factors and Outcome of Lupus Nephritis Among Children With Systemic Lupus Erthromatousus in Sohag Univeristy Hospital

systemic lupus erthrematosus is an inflamatory and autoimmune condition characterized by multisystem affection and chronic course with unpredictable flares despite potentially afffecting every oragan . kidney involvment are the most common

1 - 18 years of age All Phase N/A
D Desmond Yap, MD

The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus Nephritis

This study investigated the effect of mycophenolate mofetil and cyclosphosphamide on lymphocyte subsets in patients with proliferative lupus nephritis. Patients with biopsy-proven Class III/IV+/-V LN were randomized to received: 1) prednisolone (0.8mg/kg/day) plus CTX (1.5-2mg/kg/d) for 6 months) followed by Azathioprine (AZA) (1-1.5mg/kg/d) maintenance; OR 2) prednisolone (0.8mg/kg/d) plus MMF …

18 - 80 years of age All Phase N/A
X Xia Gao, M.D.

Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children

The goal of this prospective, open, single-arm clinical trial was to evaluate the safety and potential efficacy of CAR T cell therapy in children with refractory/recurrent lupus nephritis. The persistence and cell phenotype of CAR-T cells in vivo and CAR-T treatment-related inflammatory factors were evaluated after treatment. To explore new …

6 - 18 years of age All Phase 3
H He Huang, Doctor

CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis

A Clinical Study of the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis.

18 years of age All Phase 0
U US GSK Clinical Trials Call Center

Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN

The purpose of the OBSErve-LN study is to assess the real-world use and effectiveness of belimumab in routine practice for the treatment of adults with active LN in multiple countries of interest. This study aims to provide the first long-term (up to 5 years) assessment of renal function preservation in …

18 years of age All Phase N/A

Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN

A double-blind,placebo controlled,randomized Phase 2 study to evaluate the safety and tolerability of once-daily, oral administration of 200 or 300 mg HSK39297 tablets versus placebo in Patients With Lupus Nephritis

18 - 75 years of age All Phase 2
H Hui Luo

Phase IIa Study for IPG11406 in Patients With Lupus Nephritis

A multi-center, multi-dose phase Ib/IIa clinical study evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics, and impact on biomarkers of IPG11406 in patients with Lupus Nephritis

18 - 70 years of age All Phase 1/2
S Study Director

LUPKYNIS Drug-use Results Survey

The purpose of this study is to survey the safety of LUPKYNIS in patients with lupus nephritis under actual use conditions. In addition, information on efficacy will be collected.

15 years of age All Phase N/A

A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis

The purpose of this study is to assess the efficacy of QL1074 compared with placebo in achieving renal response after 52 weeks of therapy in subjects with Active Lupus Nephritis.

18 - 75 years of age All Phase 3

Simplify language using AI